Shay Capital’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Shay Capital’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$24.9K	Hold	10,662	–	–	﹤0.01%	464
2025 Q4	$14.4K	Buy	+10,662	New	+$15.5K	﹤0.01%	475

Other funds holding ZNTL

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Shay Capital's ZNTL Position: Q1 2026 in Review

Shay Capital held its Zentalis Pharmaceuticals (ZNTL) position steady in Q1 2026 at 10,662 shares worth $24.9K. The position accounts for ﹤0.01% of the portfolio, ranked #464.

Shay Capital first reported a position in ZNTL in Q4 2025 and has held it in 2 quarters since. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

Shay Capital held 10,662 shares of Zentalis Pharmaceuticals worth $24.9K as of Q1 2026.
Shay Capital left its Zentalis Pharmaceuticals share count unchanged in Q1 2026.
Zentalis Pharmaceuticals made up ﹤0.01% of Shay Capital's portfolio in Q1 2026, its #464 holding.
Shay Capital first reported a position in Zentalis Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Shay Capital's 13F filing for Q1 2026, filed 15 May 2026.